Home  >  News
you can get e-magazine links on WhatsApp. Click here
Patents + Font Resize -

Neurelis receives US patent for Valtoco for acute treatment of episodes of frequent seizure activity

San Diego, California
Wednesday, April 27, 2022, 12:00 Hrs  [IST]

Neurelis, Inc., a neuroscience-based company dedicated to enhancing therapeutic benefits and addressing significant unmet needs in managing CNS disorders, announced that it has secured the issuance of United States Patent No. 11,241,414 (the ‘414 Patent) for Valtoco (diazepam nasal spray) CIV for acute treatment of episodes of frequent seizure activity in adult and paediatric patients age six and older.

“Our approach to innovation seeks to improve patient outcomes with constant feedback from our patient community,” said Craig Chambliss, president and chief executive officer of Neurelis. “We continue to demonstrate this innovation through the issuance of the ‘414 patent and others under review at the US Patent and Trademark Office. We remain optimistic about our ability to extend the exclusivity of Valtoco beyond 2029.”

More than 50 million people worldwide live with epilepsy and, despite the availability of chronic, daily oral medications to help manage their seizures, many patients continue to experience recurring breakthrough seizures. If left untreated, these seizures can significantly impact quality of life and can potentially cause damage to the brain. In the US, as many as 170,000 of these patients deal with acute episodes of frequent seizure activity, sometimes referred to as “seizure clusters” or ‘’acute repetitive seizures.” As a therapy that can be both caregiver- and self-administered outside a medical setting to respond to these seizure emergencies, Valtoco empowers patients and care partners to take a proactive role in managing their disease and improving their health outcomes.

“This additional patent for Valtoco is a critical milestone that further memorializes our commitment in innovating patient-centric solutions in rare and broader CNS indications,” said Enrique Carrazza, MD, chief medical officer of Neurelis. “Combined with a robust and growing body of clinical evidence supporting the safety and effectiveness of Valtoco in the treatment of acute episodes of frequent seizure activity, this patent demonstrates our commitment and ability to overcome tough scientific challenges that are barriers to advancing care for patients with epilepsy.”

Neurelis, Inc., is a commercial-stage neuroscience company focused on the development and commercialization of therapeutics for the treatment of epilepsy and orphan neurologic disorders characterized by high unmet medical need.


* Name :     
* Email :    
  Website :  
Copyright © 2016 Saffron Media Pvt. Ltd |